PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11823761-0 2002 Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. losartan carboxylic acid 48-54 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 74-80 11823761-2 2002 Our aim was to evaluate the pharmacokinetics of losartan and E-3174 in relation to the CYP2C9 genotype. losartan carboxylic acid 61-67 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 87-93 11823761-6 2002 RESULTS: The maximum plasma concentration of E-3174 was significantly (P <.05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. losartan carboxylic acid 45-51 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 95-101 11823761-6 2002 RESULTS: The maximum plasma concentration of E-3174 was significantly (P <.05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. losartan carboxylic acid 45-51 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 119-125 11823761-6 2002 RESULTS: The maximum plasma concentration of E-3174 was significantly (P <.05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. losartan carboxylic acid 45-51 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 119-125 11823761-6 2002 RESULTS: The maximum plasma concentration of E-3174 was significantly (P <.05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. losartan carboxylic acid 45-51 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 119-125 11823761-6 2002 RESULTS: The maximum plasma concentration of E-3174 was significantly (P <.05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. losartan carboxylic acid 45-51 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 119-125 11823761-10 2002 CONCLUSION: The CYP2C9*3 allele was shown to be associated with decreased formation of E-3174 from losartan. losartan carboxylic acid 87-93 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 16-22 11408373-5 2001 Sulfaphenazole, a CYP2C9 inhibitor, blocked the formation of E-3174 at low losartan concentrations (<1 microM), whereas the inhibitory effect of triacetyloleandomycin, a CYP3A4 inhibitor, was significant only at high concentrations of losartan (>25 microM). losartan carboxylic acid 61-67 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 18-24 9542475-1 1998 BACKGROUND: Losartan is metabolized by CYP2C9 and CYP3A4 to an active metabolite, E3174, which has greater antihypertensive activity than the parent compound. losartan carboxylic acid 82-87 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 39-45 10197301-1 1999 Losartan is an angiotensin II receptor antagonist that is metabolized by CYP2C9 and CYP3A4 to a more potent antihypertensive metabolite, E3174. losartan carboxylic acid 137-142 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 73-79 9542475-13 1998 Further studies are needed to define the contribution of other isozymes, particularly CYP2C9, to the pharmacokinetics of losartan and E3174. losartan carboxylic acid 134-139 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 86-92 25977991-7 2015 CYP2C9 enzyme activity was assessed using urinary losartan/metabolite E-3174 ratio. losartan carboxylic acid 70-76 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 9551703-1 1998 OBJECTIVE: Losartan is metabolised to its active metabolite E-3174 by CYP2C9 and CYP3A4 in vitro. losartan carboxylic acid 60-66 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 70-76 9551703-13 1998 This implicates that, in man, CYP2C9 is a major enzyme for the formation of E-3174 from losartan. losartan carboxylic acid 76-82 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 30-36 7736913-10 1995 Subsequently, it was shown that rabbit anti-CYP2C9 and anti-CYP3A3/4 inhibited the oxidation of losartan to E3174 in incubations with human liver microsomes. losartan carboxylic acid 108-113 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 44-50 34210056-0 2021 Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis. losartan carboxylic acid 104-110 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 13-19 34210056-7 2021 For half-life, subjects with CYP2C9*2 or *3 carriers had longer half-lives of losartan and E-3174 than those with CYP2C9*1/*1 (MD 0.47 h; 95% CI: 0.32, 0.61 and MD 0.68 h; 95% CI: 0.44, 0.92, respectively). losartan carboxylic acid 91-97 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 29-35 34210056-8 2021 This meta-analysis suggests that the pharmacokinetics of losartan and E-3174 are associated with the CYP2C9 polymorphisms. losartan carboxylic acid 70-76 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 101-107 32186616-2 2019 Its dosage is related to the genetic characteristics of CYP2C9 enzymatic activity, which metabolizes losartan to its active form E-3174, responsible for the antihypertensive effect. losartan carboxylic acid 129-135 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 32186616-13 2019 The presence of CYP2C9*3 is associated with the need for higher doses of losartan, possibly due to a decrease in the conversion of losartan to E-3174. losartan carboxylic acid 143-149 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 16-22 24800477-0 2013 [Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. losartan carboxylic acid 116-122 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 54-60 19903527-2 2010 Additionally, the influence of optimized GRDDS on the bioavailability of Losartan and the formation extent of active metabolite E3174 by CYP2C9 polymorphism was investigated. losartan carboxylic acid 128-133 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 137-143 21870106-7 2012 In addition, losartan/E-3174 ratio doubled (P < 0.01) after BBR administration, indicating a decrease in CYP2C9 activity. losartan carboxylic acid 22-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 108-114 21841812-10 2011 CYP2C9*3/*3 subjects metabolized much less losartan into E-3174 than CYP2C9*1/*1 subjects. losartan carboxylic acid 57-63 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 22735459-9 2012 CONCLUSION: These results suggest that CYP2C9*1/*3 and CYP2C9*1/*13 are similarly associated with decreased formation of E-3174 from losartan, but the clinical effects of losartan may not be reduced by CYP2C9*1/*3 and CYP2C9*1/*13. losartan carboxylic acid 121-127 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 39-45 22735459-9 2012 CONCLUSION: These results suggest that CYP2C9*1/*3 and CYP2C9*1/*13 are similarly associated with decreased formation of E-3174 from losartan, but the clinical effects of losartan may not be reduced by CYP2C9*1/*3 and CYP2C9*1/*13. losartan carboxylic acid 121-127 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 55-61 22735459-9 2012 CONCLUSION: These results suggest that CYP2C9*1/*3 and CYP2C9*1/*13 are similarly associated with decreased formation of E-3174 from losartan, but the clinical effects of losartan may not be reduced by CYP2C9*1/*3 and CYP2C9*1/*13. losartan carboxylic acid 121-127 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 55-61 22735459-9 2012 CONCLUSION: These results suggest that CYP2C9*1/*3 and CYP2C9*1/*13 are similarly associated with decreased formation of E-3174 from losartan, but the clinical effects of losartan may not be reduced by CYP2C9*1/*3 and CYP2C9*1/*13. losartan carboxylic acid 121-127 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 55-61 23093260-1 2012 BACKGROUND: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochrome CYP2C9. losartan carboxylic acid 39-63 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 103-109 23093260-1 2012 BACKGROUND: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochrome CYP2C9. losartan carboxylic acid 65-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 103-109 20668444-4 2010 Whereas glucosamine had no significant effect on CYP activity, noscapine caused marked inhibition of CYP2C9 (4.9-fold increase in urinary losartan/E3174 ratio) and CYP2C19 (3.6-fold increase in the plasma omeprazole/5-hydroxyomeprazole ratio). losartan carboxylic acid 147-152 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 101-107 18445991-1 2008 Losartan, a selective angiotensin receptor antagonist, is mainly metabolized by CYP2C9 to an active carboxylic acid, E3174, which is pharmacologically more potent inhibitor than the parent compound. losartan carboxylic acid 117-122 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 80-86 19221727-5 2009 The AUC of E-3174 decreased significantly with a silymarin pretreatment in both CYP2C9*1/*1 and the CYP2C9*1/*3 subjects. losartan carboxylic acid 11-17 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 80-86 19221727-5 2009 The AUC of E-3174 decreased significantly with a silymarin pretreatment in both CYP2C9*1/*1 and the CYP2C9*1/*3 subjects. losartan carboxylic acid 11-17 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 100-106 18816302-1 2008 Losartan is oxidized to E3174 by cytochrome P450 2C9 (CYP2C9); it has been suggested as a useful probe drug for CYP2C9 activity. losartan carboxylic acid 24-29 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 33-52 18816302-1 2008 Losartan is oxidized to E3174 by cytochrome P450 2C9 (CYP2C9); it has been suggested as a useful probe drug for CYP2C9 activity. losartan carboxylic acid 24-29 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 54-60 18816302-1 2008 Losartan is oxidized to E3174 by cytochrome P450 2C9 (CYP2C9); it has been suggested as a useful probe drug for CYP2C9 activity. losartan carboxylic acid 24-29 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 112-118 15197523-8 2004 The urinary losartan/E3174 ratio was significantly higher in subjects with CYP2C9*1/*3 genotype (median 2.35, n=12) than in subjects with CYP2C9*1/*1 (0.71, n=58) and *1/*2 (0.85, n=10) genotypes ( P<0.05). losartan carboxylic acid 21-26 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 75-81 15289788-1 2004 UNLABELLED: Background and aim Previous data indicate that the urinary losartan/E-3174 ratio is a marker for cytochrome P450 (CYP) 2C9 activity in vivo. losartan carboxylic acid 80-86 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 109-134 15289788-6 2004 RESULTS: The urinary losartan/E-3174 ratio in the various genotypes was as follows: 1.85 +/- 2.4 (mean +/- SD) for CYP2C9*1/*1, 14.6 for CYP2C9*1/*5, 4.2 for CYP2C9*1/*6, 188 for CYP2C9*5/*6, 11.6 for CYP2C9*5/*8, 0.44 +/- 0.13 (mean +/- SD) for CYP2C9*1/*8, 2.2 for CYP2C9*8/*11, and 5.72 +/- 4.5 (mean +/- SD) for CYP2C9*1/*11. losartan carboxylic acid 30-36 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 115-121 15289788-8 2004 The urinary losartan/E-3174 ratio of the single CYP2C9*1/*6 subject was higher than the 95% confidence interval of the mean of the CYP2C9*1/*1 group (0.0-3.7), whereas the metabolic ratio of the CYP2C9*8/*11 carrier was inside the 95% confidence interval of the means of the CYP2C9*1/*1 and CYP2C9*1/*11 groups (0.0-18). losartan carboxylic acid 21-27 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 48-54 12820813-0 2003 Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. losartan carboxylic acid 13-18 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 39-58 12820813-8 2003 A significant association between CYP2C9 genotype and losartan to E3174 formation clearance was observed, such that 50% of the variability was accounted for by the genotype. losartan carboxylic acid 66-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 34-40 12235444-13 2002 However, phenytoin inhibited the CYP2C9-mediated conversion of losartan to E3174. losartan carboxylic acid 75-80 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 33-39